Samsung Medical (601567) announced on the evening of December 7 that the company intends to repurchase shares with its own funds in a centralized bidding transaction for the implementation of employee stock ownership plans or equity incentive plans, with a total amount of repurchase funds not less than 1500 million yuan, not more than 300 million yuan, repurchase ** no more than 21 yuan shares. The company's **latest** price is 18$82 shares.
It is estimated that the number of shares repurchased this time will be about 714290,000 shares to 14.28570,000 shares, accounting for 051%-1.01%。The repurchase period is 6 months from the date of approval of the share repurchase plan by the general meeting of shareholders.
As of September 30, 2023, the company's total assets were 1786.9 billion yuan, net assets of 1061.2 billion yuan. Assuming that the upper limit of 300 million yuan of repurchase funds is fully used, the proportion of repurchase funds to total assets and net assets is83%, which is relatively small.
According to the Company's current operational, financial and future development plans, the repurchase will not have a material adverse impact on the Company's continuing operations and future development, nor will it have a material adverse impact on the Company's profitability, debt performance ability and research and development capabilities.